SETTING: Although approximately 0.5 million cases of multidrug-resistant tuberculosis (MDR-TB) occur globally each year, surveillance data are limited. Botswana is one of the few high TB burden countries to have carried out multiple anti-tuberculosis drug resistance surveys (in 1995-1996, 1999 and 2002). OBJECTIVE: In 2007-2008, we conducted the fourth national survey of anti-tuberculosis drug resistance in Botswana to assess anti-tuberculosis drug resistance, including trends over time. In the previous survey, 0.8% (95%CI 0.4-1.5) of new patients and 10.4% (95%CI 5.6-17.3) of previously treated patients had MDR-TB. DESIGN: During the survey period, eligible specimens from all new sputum-smear positive TB patients and from all TB patients with history of previous anti-tuberculosis treatment underwent mycobacterial culture and anti-tuberculosis drug susceptibility testing (DST). RESULTS: Of 924 new TB patients and 137 with previous anti-tuberculosis treatment with DST results, respectively 23 (2.5%, 95%CI 1.6-3.7) and 9 (6.6%, 95%CI 3.3-11.7) had MDR-TB. The proportion of new TB patients with MDR-TB has tripled in Botswana since the previous survey. CONCLUSION: Combatting drug-resistant TB will require the scale-up of MDR-TB diagnosis and treatment to prevent the transmission of MDR-TB and strengthening of general TB control to prevent the emergence of resistance.
SETTING: Although approximately 0.5 million cases of multidrug-resistant tuberculosis (MDR-TB) occur globally each year, surveillance data are limited. Botswana is one of the few high TB burden countries to have carried out multiple anti-tuberculosis drug resistance surveys (in 1995-1996, 1999 and 2002). OBJECTIVE: In 2007-2008, we conducted the fourth national survey of anti-tuberculosis drug resistance in Botswana to assess anti-tuberculosis drug resistance, including trends over time. In the previous survey, 0.8% (95%CI 0.4-1.5) of new patients and 10.4% (95%CI 5.6-17.3) of previously treated patients had MDR-TB. DESIGN: During the survey period, eligible specimens from all new sputum-smear positive TBpatients and from all TBpatients with history of previous anti-tuberculosis treatment underwent mycobacterial culture and anti-tuberculosis drug susceptibility testing (DST). RESULTS: Of 924 new TBpatients and 137 with previous anti-tuberculosis treatment with DST results, respectively 23 (2.5%, 95%CI 1.6-3.7) and 9 (6.6%, 95%CI 3.3-11.7) had MDR-TB. The proportion of new TBpatients with MDR-TB has tripled in Botswana since the previous survey. CONCLUSION: Combatting drug-resistant TB will require the scale-up of MDR-TB diagnosis and treatment to prevent the transmission of MDR-TB and strengthening of general TB control to prevent the emergence of resistance.
Authors: Taraz Samandari; Tefera B Agizew; Samba Nyirenda; Zegabriel Tedla; Thabisa Sibanda; Nong Shang; Barudi Mosimaneotsile; Oaitse I Motsamai; Lorna Bozeman; Margarett K Davis; Elizabeth A Talbot; Themba L Moeti; Howard J Moffat; Peter H Kilmarx; Kenneth G Castro; Charles D Wells Journal: Lancet Date: 2011-04-12 Impact factor: 79.321
Authors: A D Harries; H T Banda; M J Boeree; S Welby; J J Wirima; V R Subramanyam; D Maher; P Nunn Journal: Int J Tuberc Lung Dis Date: 1998-12 Impact factor: 2.373
Authors: Lillian Mtei; Mecky Matee; Oliver Herfort; Muhammad Bakari; C Robert Horsburgh; Richard Waddell; Bernard F Cole; Jenni M Vuola; Susan Tvaroha; Barry Kreiswirth; Kisali Pallangyo; C Fordham von Reyn Journal: Clin Infect Dis Date: 2005-04-12 Impact factor: 9.079
Authors: E A Talbot; N M Hone; H J Moffat; E J Lee; T L Moeti; K Mokobela; M Mbulawa; N J Binkin; C D Wells; T A Kenyon Journal: Int J Tuberc Lung Dis Date: 2003-08 Impact factor: 2.373
Authors: E S Click; J Chirenda; S Kibias; H J Menzies; J E Oeltmann; C Sentle; T Muribe; T D Lere; R Makombe; S Bamrah; B K Moore; K P Cain Journal: Int J Tuberc Lung Dis Date: 2014-11 Impact factor: 2.373
Authors: N Quispe; L Asencios; C Obregon; G E Velásquez; C D Mitnick; M Lindeborg; H Jave; L Solari Journal: Int J Tuberc Lung Dis Date: 2020-02-01 Impact factor: 2.373
Authors: Sanghyuk S Shin; Chawangwa Modongo; Yeonsoo Baik; Christopher Allender; Darrin Lemmer; Rebecca E Colman; David M Engelthaler; Robin M Warren; Nicola M Zetola Journal: J Infect Dis Date: 2018-11-05 Impact factor: 5.226
Authors: Collins Timire; John Z Metcalfe; Joconiah Chirenda; Jerod N Scholten; Barbara Manyame-Murwira; Mkhokheli Ngwenya; Ronnie Matambo; Kelvin Charambira; Herbert Mutunzi; Nico Kalisvaart; Charles Sandy Journal: Int J Infect Dis Date: 2019-07-27 Impact factor: 12.074
Authors: Ariadna Rando-Segura; María Luisa Aznar; María Milagros Moreno; Mateu Espasa; Elena Sulleiro; Cristina Bocanegra; Eva Gil; Arlete N E Eugénio; Carlos Escartin; Adriano Zacarias; Josep Vegue; Domingos Katimba; María Carmen Vivas; Estevao Gabriel; María Concepción Marina; Jacobo Mendioroz; María Teresa López; Tomas Pumarola; Israel Molina; María Teresa Tórtola Journal: Emerg Infect Dis Date: 2018-03 Impact factor: 6.883
Authors: Nazir Ismail; Farzana Ismail; Shaheed V Omar; Linsay Blows; Yasmin Gardee; Hendrik Koornhof; Philip C Onyebujoh Journal: Afr J Lab Med Date: 2018-12-06
Authors: N Ruswa; F Mavhunga; J C Roscoe; A Beukes; E Shipiki; J van Gorkom; S Sawadogo; S Agolory; H Menzies; D Tiruneh; B Makumbi; B Bayer; A Zezai; P Campbell; H Alexander; N Kalisvaart; N Forster Journal: Int J Tuberc Lung Dis Date: 2019-07-01 Impact factor: 2.373